Search

Although deregulation of EPHB signaling has been shown to be an important step in colorectal tumorigenesis, the role of EPHB6 in this process has not been investigated. We found here that manipulation of EPHB6 levels in colon cancer cell lines has no effect on their motility and growth on a solid substrate, soft agar or in a xenograft mouse model. We then used an EphB6 knockout mouse model to show that EphB6 inactivation does not efficiently initiate tumorigenesis in the intestinal tract. In addition, when intestinal tumors are initiated genetically or pharmacologically in EphB6+/+ and EphB6−/− mice, no differences were observed in animal survival, tumor multiplicity, size or histology, and proliferation of intestinal epithelial cells or tumor cells. However, reintroduction of EPHB6 into colon cancer cells significantly reduced the number of lung metastasis after tail-vein injection in immunodeficient mice, while EPHB6 knockdown in EPHB6-expressing cells increased their metastatic spread. Consistently, although EPHB6 protein expression in a series of 130 primary colorectal tumors was not associated with patient survival, EPHB6 expression was significantly lower in lymph node metastases compared to primary tumors. Our results indicate that the loss of EPHB6 contributes to the metastatic process of colorectal cancer.

Los receptores EPH (receptores de efrina) constituyen la subfamilia más grande de los receptores tirosina quinasas en mamífero. Se unen a las efrinas, ancladas a las membranas celulares mediante un enlace glicosilfosfatidilinositol (GPI) (efrinas de tipo A) o mediante una dominio transmembrana seguido por un dominio citoplasmático (efrinas de tipo B). El complejo receptor-ligando activa una cascada de señalización tanto en las células que expresan los receptores EPH como en las células adyacentes, que expresan las efrinas. Este mecanismo se denomina “forward” y “reverse signalling”, respectivamente. La interacción entre receptor y su ligando puede desencadenar una amplia gama de respuestas celulares incluyendo la adhesión, repulsión y la segregación/posicionamiento celular durante la separación de los tejidos en las primeras fases de desarrollo embrionario. Los mecanismos que regulan estas distintas respuestas dependen en gran medida del tipo celular y del tejido. Aunque, los receptores EPH han sido ampliamente caracterizados para sus funciones durante el desarrollo embrionario, se encuentran re-expresados en una variedad de tumores malignos humanos. No obstante, dependiendo del tipo de tumor, de su estadio y de la actividad quinasa, los receptores EPH pueden actuar induciendo o inhibiendo la progresión del cáncer. Los receptores EPH de tipo B están involucrados en la homeostasis del epitelio intestinal y la pérdida de función de estos receptores es un evento clave en la progresión del cáncer de colon, sobretodo de adenoma a carcinoma. El receptor EPHA3, identificado y aislado por primera vez ellas membranas de células pre-B de leucemia linfoblástica aguda, se encuentra ampliamente expresado durante el desarrollo embrionario, particularmente en el tejido nervioso y corazón. Tal como se espera de su primera identificación, se ha demostrado que también está involucrado en muchos tipos de cáncer. Los efectos inactivantes de distintas mutaciones somáticas encontradas en varios tipos de cáncer, sugieren fuertemente que la proteína EPHA3 suprime las propiedades de las células cancerígenas a través un mecanismo que dependería de su unión con la efrina y de su actividad quinasa. Dos estudios independientes de secuenciación de ADN empleando técnicas de nueva generación, descubrieron una alta frecuencia de mutaciones en EPHA3 en una amplia cohorte de tumores de colon humano y, más importante, la mayoría de estas mutaciones se descubrieron afectar la actividad quinasa o el dominio de unión con el ligando. Sin embargo, la función de EPHA3 en la tumorigenesis intestinal no ha sido investigada a fondo. Por lo tanto, en este estudio se utilizaron dos líneas celulares de cáncer de colon humano, LS174 y DLD1, para sobre-expresar de forma inducible por doxiciclina el receptor EPHA3. Hemos observado que la reintroducción de EPHA3 en líneas de cáncer de colon no afecta el crecimiento de las células cultivadas en sustratos sólidos, en medio semi-solido (soft-agar) o como xenotrasplantes en ratones inmunodeprimidos. Además, se utilizó un modelo transgénico de ratón en el que el gen EphA3 ha sido suprimido y descubrimos que la inactivación específica de uno o los dos alelos de este gen no inicia el proceso tumorígenico en el intestino de los ratones. Tampoco observamos cambios en el tamaño o en el número de tumores intestinales en ratones donde la tumorigenesis intestinal se inició genéticamente (modelo de ratón Apcmin/+) o farmacológicamente (tratamiento con azoximetano). También hemos observado que la sobreexpresión de EPHA3 en células de cáncer de colon no afecta su capacidad de migración o de invasión en ensayos in vitro. Para profundizar el papel de EPHA3 en el proceso metastático, se usó un modelo murino de metástasis de pulmón observando que la reintroducción de EPHA3 en células de cáncer de colon inyectadas en las colas de ratones inmunodeprimidos no altera su capacidad migratoria y de generar metástasis en otros órganos in vivo. Estos resultados confirman los datos de inmunhistoquimica donde observamos ausencia de diferencias en los niveles de tinción de EPHA3 en los nódulos linfáticos respeto a los tumores primarios de pacientes con cáncer colorrectal localmente avanzado (estadio Dukes C). Por último, el análisis inmuhistoquimico de los niveles de tinción de EPHA3 en pacientes con cáncer colorrectal (estadio Dukes C) no reveló ninguna correlación con la supervivencia y otras características clinicopatologicas de estos pacientes. En conclusión, en este estudio, reportamos que el mecanismo de señalización quinasa dependiente del receptor EPHA3, aunque está frecuentemente inactivado en cáncer colorrectal, no juega un papel como supresor de la tumorigenesis intestinal durante ningún estadio de la progresión del tumor, tanto in vitro como in vivo. Estos resultados, esclarecen el papel de EPHA3 en cáncer colorrectal y evidencian la importancia de estudios funcionales para confirmar el papel de los genes identificados como posibles candidatos de la progresión tumoral empleando técnicas avanzadas de secuenciación genómica de tumores., EPHs, which make up the largest family of mammalian receptor tyrosine kinases, bind cell surface–associated Ephrins that have either a glycosylphosphatidylinositol (GPI) membrane anchor (A-type Ephrins) or a transmembrane region followed by a conserved cytoplasmatic tail (B-type Ephrins). Clustering of EPH receptors and their ligand at the surface of adjacent cells activates downstream signaling in both the EPH- and Ephrin-expressing cells, termed forward and reverse signaling, respectively. Eph–ephrin interactions can trigger a wide array of cellular responses including cell adhesion, repulsion and cell sorting/positioning during tissue boundary and the mechanisms leading to these different responses are highly dependent on the cell type and tissue context. Although most extensively characterized for their roles in development, Eph receptors are re-expressed in a variety of human malignancies. However, depending on the tumor type, disease stage and kinase function, EPH overexpression can promote or inhibit tumor progression. The role of EPHB receptors was discovered to be involved in the homeostasis of the normal intestinal epithelium and loss of function of B-type EPHs is a key event of colorectal cancer progression, mainly from adenoma to carcinoma. The EPHA3 receptor, originally recognized and isolated from membranes of pre-B acute lymphoblastic leukemia cells, is widely expressed during embryonic development, with the highest levels occurring in the nervous system and heart. As expected from its first identification, it was then implicated as having a key role in many cancers. The inactivating effects of many somatic mutations found in different cancers, strongly suggest that wild-type EPHA3 receptor suppresses the malignant properties of cancer cells in an ephrin-and kinase-dependent manner. Two independent studies of next-generation DNA sequencing using large cohorts of human colorectal cancer samples showed unexpected high mutation frequency in EPHA3 and, importantly many of these mutations were found to impair the kinase activity or ligand binding domain. However, the function of EPHA3 in intestinal tumorigenesis has not been thoroughly investigated. Thus, in this study we generated a doxycycline-dependent EPHA3 overexpression system in two different human colon cancer cell lines, LS174 and DLD1. Importantly, we found that the reintroduction of EPHA3 in colon cancer cells did not affect their growth on a solid substrate, soft agar or as xenografts in immunodeficient mice. Moreover, using a full knockout mouse model we show that targeted inactivation of one or both alleles of EphA3 did not initiate the tumorigenic process in the murine intestine, and had no effects on tumor size/multiplicity after tumor initiation either genetically or pharmacologically. Restoring EPHA3 levels in colon cancer cells did not modulate their motility/invasion in vitro. In addition, to more closely investigate the role of EPHA3 in the metastatic process, we used a mouse model of lung metastasis and found that the ectopic overexpression of EPHA3 in human colon cancer cells, injected in to the tail vein of immunodeficient mice, does not affect their capability in vivo to migrate and colonize distant organs. These results are consistent with our immunohistochemistry data showing no EPHA3 expression differences in primary Dukes C tumors and matched lymph node metastases. Finally, immunohistochemical analysis of EPHA3 tumor levels did not reveal associations with survival or clinicopathological features of Duke C colorectal cancer patients. In conclusion, here we report that the kinase dependent signaling of EPHA3, despite frequently inactivated in colorectal cancer, does not play a tumor suppressive function in intestinal tumorigenesis and, importantly, in any stage of the cancer progression using either in vivo or in vivo experimental models. These results significantly contribute to our understanding of the role of EPH signaling during colorectal carcinogenesis, and highlighting the need for detailed functional studies to confirm the relevance of putative cancer driver genes identified in sequencing efforts of the cancer genome.

Tyrosine kinase; EPHA3; Colorectal cancer Tirosina-cinasa; EPHA3; Càncer colorectal Tirosina quinasa; EPHA3; Cáncer colorrectal EPH signaling deregulation has been shown to be important for colorectal carcinogenesis and genome-wide sequencing efforts have identified EPHA3 as one of the most frequently mutated genes in these tumors. However, the role of EPHA3 in colorectal cancer has not been thoroughly investigated. We show here that ectopic expression of wild type EPHA3 in colon cancer cells did not affect their growth, motility/invasion or metastatic potential in vivo. Moreover, overexpression of mutant EPHA3 or deletion of the endogenous mutant EPHA3 in colon cancer cells did not affect their growth or motility. EPHA3 inactivation in mice did not initiate the tumorigenic process in their intestine, and had no effects on tumor size/multiplicity after tumor initiation either genetically or pharmacologically. In addition, immunohistochemical analysis of EPHA3 tumor levels did not reveal associations with survival or clinicopathological features of colorectal cancer patients. In conclusion, we show that EPHA3 does not play a major role in colorectal tumorigenesis. These results significantly contribute to our understanding of the role of EPH signaling during colorectal carcinogenesis, and highlighting the need for detailed functional studies to confirm the relevance of putative cancer driver genes identified in sequencing efforts of the cancer genome.

In questo documento, partendo dall'approccio teorico al problema dell'eterogeneità semantica sviluppato nell'ambito del progetto Edamok, si cercherà di spiegare come tale approccio possa essere declinato in una reale soluzione al problema della comunicazione nel campo del commercio elettronico, in particolare nel mondo del Business-to-Business. I primi paragrafi saranno dedicati alla descrizione del mondo B2B nei suoi diversi aspetti mentre di seguito, illustreremo il problema della comunicazione e dell'interazione tra soggetti compratori e venditori e le soluzioni fino ad ora proposte. Infine, spiegheremo, anche attraverso la presentazione della attuale fase di sperimentazione del progetto, come l'approccio di Distributed Knowledge Management adottato da Edamok possa risultare efficace anche nel mondo dell'E-Commerce.

International audience; The article focuses on 12 letters written in Bytom by the papal doctor Michele Mercati to the cardinal Ippolito Aldobrandini at that time legato a latere in Poland. These letters reveal an involvement of the physician in a field apparently very distant from his specific competence : the political mediation. First, the article reconstructs his specific political role in a thorny international affaire. Second, it considers his diplomatic intervention in relation to the cultural and political activities he carried out during the Polish journey. Through this analysis, situated at the intersection of two very dynamix historiographic field, we would like to shed a new light both on diplomatic practices and the identity of the political mediator and on the complex profil of physician at the early modern period.